Aeglea BioTherapeutics Provides Clinical Progress and Regulatory Update for Homocystinuria Program ...Middle East

PR Newswire - News
AUSTIN, Texas, Oct. 4, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced that dosing in the third cohort of...

Hence then, the article about aeglea biotherapeutics provides clinical progress and regulatory update for homocystinuria program was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Aeglea BioTherapeutics Provides Clinical Progress and Regulatory Update for Homocystinuria Program )

Apple Storegoogle play

Last updated :

Also on site :

Most viewed in News


Latest News